Financial Scoreboard: Becton Dickinson and Medtronic

Revenues for Becton, Dickinson and Co. (BD; Franklin Lakes, NJ) increased 10% to $3.418 billion for the year. The company attributes the growth to recent acquisitions. Reported earnings for share $1.04 for 1999.

U.S. revenues increased three percent to $1.748 billion, and revenues outside the U.S. increased 17%. The company's medical systems division reported revenues of $1.924 billion, revenues from biosciences were $986 million, and revenues from preanalytical solutions were $509 million.

For the fourth quarter, revenues increased seven percent to $902 million. Reported earnings per share were $.29. Medical systems revenues were $521 million, biosciences were $255 million, and preanalytical solutions were $126 million.

Medtronic: Second Quarter Results

The company's revenues increased to $1.1 billion for the second quarter. The growth was helped by increases in pacemaker sales, implantable defribillator sales, and the increased prospects of the Neurological and Spinal organizations.

The cardiac rhythm management quarterly product line posted revenues of $611.6 million. Pacemaker revenues grew 13% from the launches of the Medtronic Sigma and the Vitatron Collection II and Vita pacemakers.

The company's spinal and neurosurgery products posted a 40% revenue from the quarter. The vascular lines rose to $164.3 million. Worldwide cardiac surgery revenues increased 19%.

Edited by Andrea King